A drug used to treat Ebola patients has shown "very promising" early results in a trial of people admitted to hospital with coronavirus, scientists said.
Patients given remdesivir had a recovery time that was almost a third faster than those given a placebo, the first results from an international clinical trial showed.
Preliminary results also suggested a survival benefit, with a lower mortality rate of 8% for the group receiving the drug, compared with 11.6% for the placebo group, the National Institute of Allergy and Infectious Diseases (NIAD) said.
US medical chief Dr Anthony Fauci, the head of the National Institutes of Allergy and Infectious Diseases, has also hailed the trial's results. "The data shows that remdesivir has a
Read more on mirror.co.uk